Tarsus Pharmaceuticals Inc (TARS)
Healthcare
Biotechnology
59.00 $
-0.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Tarsus Pharmaceuticals Inc (TARS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.6% of the shares are freely tradable; institutional investors hold 109.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
109.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
74.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
12.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
43Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Deep Track Capital, LP | 8.37 | 3,600,000 | +19.8 | 03/31/2026 |
| BlackRock Inc | 8.26 | 3,552,612 | -6.3 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 7.78 | 3,346,025 | +0.3 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 5.96 | 2,562,154 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 5.58 | 2,399,560 | +5.6 | 12/31/2025 |
| HHG PLC | 5.21 | 2,240,963 | +16.1 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 4.52 | 1,944,272 | -4.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.09 | 1,760,541 | +0.0 | 03/31/2026 |
| Jennison Associates LLC | 3.98 | 1,712,124 | -23.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.99 | 1,287,389 | +0.4 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.